Novo Nordisk løftes kraftigt af FDA-melding om stop for outsourcing
30/4 19:46
Uddrag fra investing.com: Shares in Novo Nordisk (CSE:NOVOb) climbed more than 6% on Thursday after the U.S. Food and Drug Administration proposed restricting the compounding of weight-loss medications. The FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, stating there is no clinical need for outsourcing facilities to compound these drugs. A trader […]...